Roche Shares Update on the Investigation of Satralizumab for Bone Health and the SHIELD DMD Study

February 20, 2026

On February 20, 2026, Roche shared an important update in a community letter regarding their work in bone health in Duchenne and the SHIELD DMD study.

Read more by visiting their community letter here.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open